Press releases

Orchard Therapeutics Announces Appointments of Marc Dunoyer and Charlie Rowland to Board of Directors

Orchard Therapeutics today announced the appointments of Marc Dunoyer and Charlie Rowland to its board of directors as independent directors

Read more

Orchard Therapeutics’ OTL-200 Receives Rare Pediatric Disease Designation from FDA for Treatment of Metachromatic Leukodystrophy

Orchard’s fourth Rare Pediatric Disease Designation for autologous ex vivo gene therapy

Read more

Orchard Therapeutics Expands US Presence with New Corporate Office in Boston

Orchard Therapeutics today announced the opening of a new U.S. office in Boston’s Seaport District. The new Boston office builds upon the company’s footprint in London as well as Foster City and Menlo Park, California

Read more

GSK signs strategic agreement to transfer rare disease gene therapy portfolio to Orchard Therapeutics

GSK and Orchard Therapeutics today announced a strategic agreement, under which GSK will transfer its portfolio of approved and investigational rare disease gene therapies to Orchard, securing the continued development of the programmes and access for patients

Read more

Orchard Therapeutics Strengthens Executive Leadership Team with Appointment of Chief Commercial Officer and General Counsel

Orchard Therapeutics announces two key additions to its executive leadership team, appointing Jason Meyenburg as chief commercial officer and John Ilett as general counsel & company secretary

Read more